Views & Analysis Healthcare evidence development: guilty until proven innocen... Pharma must prepare its case meticulously to support its new drug applications.
Views & Analysis Behind the buzz of real-world data and real-world evidence Putting the who, where and why of real-world studies into context.
Views & Analysis Integrating patient insights and real-world data: the future... Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
Views & Analysis A new age: the real-world development pathway Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Views & Analysis Outcomes-based medicine demands real-world evidence RWE must become a fundamental accompaniment to traditional RCT data.
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
News Argenx pens $2.2bn deal to buy autoimmune biotech Forte Netherlands- and Belgium-based argenx has agreed to buy US biotech Forte Bio for up to $2.2bn, bolstering its autoimmune disease pipeline.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
